Literature DB >> 32355909

Prioritizing outcome preferences in patients with ocular hypertension and open-angle glaucoma using best-worst scaling.

Jimmy T Le1, Amanda K Bicket2, Ellen M Janssen3, Davinder Grover4, Sunita Radhakrishnan5, Steven Vold6, Michelle E Tarver7, Malvina Eydelman8, John F P Bridges9, Tianjing Li1.   

Abstract

Purpose: To quantify patients' preferences for glaucoma outcomes and use this information to prioritize outcomes that are important to patients. Design: A cross-sectional study using best-worst scaling object case (BWS). Participants: Two hundred seventy-four participants newly diagnosed with ocular hypertension or mild to moderate open angle glaucoma from three private practices and one academic medical center in the United States.
Methods: We designed a preference-elicitation survey based on findings from 25 semi-structured, qualitative interviews with patients with glaucoma (reported elsewhere). The survey asked participants to rate the importance of 13 glaucoma outcomes on a Likert scale as a warm-up exercise followed by completion of 13 BWS tasks. For each task, we presented participants a subset of four outcomes from the possible thirteen, and participants chose the most important and least important outcome. Outcomes included in the survey pertain to maintaining ability to perform vision-dependent activities of daily living (e.g., driving), maintaining visual function and perception (e.g., depth perception), minimizing need to take glaucoma drops, not experiencing ocular surface symptoms (e.g., red eyes, teary eyes), and having adequate control of intraocular pressure (IOP). We administered the survey online and analyzed response patterns using conditional logistic regression to determine the relative importance of different outcomes. Main outcome: Ordinal ranking of glaucoma outcomes based on preference weights.
Results: Between September 1, 2017 and February 28, 2018, we invited 1035 patients to complete our survey, among whom 274 (26%) responded. Most participants were older than 65 years of age (146/274, 53%) and currently on IOP-lowering drops (179/274, 65%). Participants identified that outcomes with the largest relative importance weight were having "adequate IOP control" and ability to "drive a car during the day," and the outcomes with the smallest relative importance weights were "maintaining appearance of the eye" and "reducing the number of IOP-lowering drops". Conclusions: Determining the relative importance of glaucoma outcomes to patients can help researchers design studies that may better inform clinical and regulatory decision-making. Although IOP is an outcome that researchers often measure in glaucoma clinical trials, patients also prioritized outcomes related to the ability to perform vision-dependent activities such as driving.

Entities:  

Year:  2019        PMID: 32355909      PMCID: PMC7192342          DOI: 10.1016/j.ogla.2019.08.007

Source DB:  PubMed          Journal:  Ophthalmol Glaucoma        ISSN: 2589-4196


  25 in total

1.  Views of glaucoma patients on aspects of their treatment: an assessment of patient preference by conjoint analysis.

Authors:  Jonathan S Bhargava; Bakula Patel; Alexander J E Foss; Anthony J Avery; Anthony J King
Journal:  Invest Ophthalmol Vis Sci       Date:  2006-07       Impact factor: 4.799

Review 2.  Quantifying benefit-risk preferences for medical interventions: an overview of a growing empirical literature.

Authors:  A Brett Hauber; Angelyn O Fairchild; F Reed Johnson
Journal:  Appl Health Econ Health Policy       Date:  2013-08       Impact factor: 2.561

3.  Discrete Choice Experiment Response Rates: A Meta-analysis.

Authors:  Verity Watson; Frauke Becker; Esther de Bekker-Grob
Journal:  Health Econ       Date:  2016-04-27       Impact factor: 3.046

4.  Constructing experimental designs for discrete-choice experiments: report of the ISPOR Conjoint Analysis Experimental Design Good Research Practices Task Force.

Authors:  F Reed Johnson; Emily Lancsar; Deborah Marshall; Vikram Kilambi; Axel Mühlbacher; Dean A Regier; Brian W Bresnahan; Barbara Kanninen; John F P Bridges
Journal:  Value Health       Date:  2013 Jan-Feb       Impact factor: 5.725

Review 5.  Primary open-angle glaucoma.

Authors:  Robert N Weinreb; Christopher K S Leung; Jonathan G Crowston; Felipe A Medeiros; David S Friedman; Janey L Wiggs; Keith R Martin
Journal:  Nat Rev Dis Primers       Date:  2016-09-22       Impact factor: 52.329

Review 6.  Biomarkers and surrogate endpoints in glaucoma clinical trials.

Authors:  Felipe A Medeiros
Journal:  Br J Ophthalmol       Date:  2014-07-17       Impact factor: 4.638

Review 7.  Collaborative normal tension glaucoma study.

Authors:  Douglas R Anderson
Journal:  Curr Opin Ophthalmol       Date:  2003-04       Impact factor: 3.761

8.  Developing a preference-based Glaucoma Utility Index using a discrete choice experiment.

Authors:  Jennifer M Burr; Mary Kilonzo; Luke Vale; Mandy Ryan
Journal:  Optom Vis Sci       Date:  2007-08       Impact factor: 1.973

9.  Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial.

Authors:  Anders Heijl; M Cristina Leske; Bo Bengtsson; Leslie Hyman; Boel Bengtsson; Mohamed Hussein
Journal:  Arch Ophthalmol       Date:  2002-10

Review 10.  A framework for organizing and selecting quantitative approaches for benefit-harm assessment.

Authors:  Milo A Puhan; Sonal Singh; Carlos O Weiss; Ravi Varadhan; Cynthia M Boyd
Journal:  BMC Med Res Methodol       Date:  2012-11-19       Impact factor: 4.615

View more
  2 in total

1.  Artificial Intelligence for Glaucoma: Creating and Implementing Artificial Intelligence for Disease Detection and Progression.

Authors:  Lama A Al-Aswad; Rithambara Ramachandran; Joel S Schuman; Felipe Medeiros; Malvina B Eydelman
Journal:  Ophthalmol Glaucoma       Date:  2022-02-24

2.  Priorities and Treatment Preferences among Surgery-Naive Patients with Moderate to Severe Open-Angle Glaucoma.

Authors:  Amanda K Bicket; Jimmy T Le; Carol Yorkgitis; Tianjing Li
Journal:  Ophthalmol Glaucoma       Date:  2020-05-16
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.